Raisio: Pekka Kuusniemi will leave his position as Raisio plc's CEO in June

Raisio plc, Stock Exchange Release on February 14, 2024 at 9.00 a.m. EET

Pekka Kuusniemi who has been leading Raisio Group as CEO since November 2017 has decided to leave the company. He will continue as CEO until June 15th, 2024. The Board of Directors has initiated a search for a successor.

Chairman of the Board of Directors, Arto Tiitinen: "During his time as Raisio's CEO Pekka Kuusniemi has built for the company a solid foundation which is based on purpose and values. He has been leading the company successfully through the challenges caused by pandemic time and by Russian invasion to Ukraine and he has been able to restore company profitability despite high inflation. I wish him all the best of success for the future!"

"My years as Raisio's CEO have been very interesting and times have been exceptionally challenging. Raisio is in strong shape and ready for further growth so I think it is now the right time for me to look into future opportunities. The current financial period is already 17th for me as a leader of an international industrial company and I'm convinced that with this experience there will be interesting opportunities also in the future. My sincere thanks to the Board of Directors, to the Executive Committee and to all Raisio employees for all these years. I wish you every success also in the future", Pekka Kuusniemi says.

Further information:

Arto Tiitinen, Chairman of the Board of Directors, Raisio plc, tel. [phone]

RAISIO PLC
At Raisio, we make food from the heart, with the aim of bringing health to ourselves and the Earth. We keep creating better plant-based and heart-healthy products so that eating healthily and within the Earth's ecological capacity can be a pleasure. Our strong brands, such as Benecol®, Härkis® and Elovena®, turn our ambitions into reality. Through our responsibility work, we make the hard choices for consumers, so that they can choose Raisio products with confidence. We have around 350 healthy food colleagues in seven countries and export to more than 40 markets around the world. Raisio's shares are listed on Nasdaq Helsinki Ltd. In 2023, the Group's comparable net sales for continuing operations were EUR 219.5 million and the comparable EBIT was EUR 22.7 million. www.raisio.com

© 2024 GlobeNewswire (Europe)

Gewinner im Megamarkt

Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!

Hier klicken